Palliative medicine reports · 2026
Palliative Management of Malignant Esophago-Tracheobronchial Fistula Using Covered Self-Expandable Metallic Stents: A Single-Center Case Series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eguchi Keisuke, Nakajima Takahiro, Terashima Takeshi
Аннотация
BACKGROUND: Malignant esophago-tracheobronchial fistula (ETBF) is a devastating complication of thoracic malignancies, especially advanced esophageal cancer. Covered self-expandable metallic stents (CSMSs) have emerged as a minimally invasive palliative option.
METHODS: Between May 2015 and June 2021, seven patients with malignant ETBF (five men and two women; mean age 63 ± 5.8 years) underwent CSMS placement at our institution. Primary diseases included five esophageal cancers and two metastatic mediastinal carcinomas. Clinical characteristics, technical success, complications, and outcomes were retrospectively reviewed.
RESULTS: No intraoperative mortality occurred. All patients experienced improvement in dysphagia and/or airway aspiration, allowing resumption of oral intake, which was maintained for a median of 62 days (range, 10-124 days). Median post-stenting survival was 104 days (range, 14-250 days).
CONCLUSION: CSMS placement is a safe and effective palliative treatment for malignant ETBF, preventing aspiration pneumonia and restoring oral intake, thereby supporting home-based care.
METHODS: Between May 2015 and June 2021, seven patients with malignant ETBF (five men and two women; mean age 63 ± 5.8 years) underwent CSMS placement at our institution. Primary diseases included five esophageal cancers and two metastatic mediastinal carcinomas. Clinical characteristics, technical success, complications, and outcomes were retrospectively reviewed.
RESULTS: No intraoperative mortality occurred. All patients experienced improvement in dysphagia and/or airway aspiration, allowing resumption of oral intake, which was maintained for a median of 62 days (range, 10-124 days). Median post-stenting survival was 104 days (range, 14-250 days).
CONCLUSION: CSMS placement is a safe and effective palliative treatment for malignant ETBF, preventing aspiration pneumonia and restoring oral intake, thereby supporting home-based care.